Document Type
Article
Department/Program
Natural Science & Mathematics
Journal Title
Critical Reviews in Biochemistry and Molecular Biology
Pub Date
10-2017
Publisher
Taylor and Francis
Volume
52
Issue
5
Journal Article URL
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944845/
First Page
543
Abstract
Over 20 years ago, sphingosine-1-phosphate (S1P) was discovered to be a bioactive signaling molecule. Subsequent studies later identified two related kinases, sphingosine kinase 1 and 2, which are responsible for the phosphorylation of sphingosine to S1P. Many stimuli increase sphingosine kinase activity and S1P production and secretion. Outside the cell, S1P can bind to and activate five S1P-specific G protein-coupled receptors (S1PR1–5) to regulate many important cellular and physiological processes in an autocrine or paracrine manner. S1P is found in high concentrations in the blood where it functions to control vascular integrity and trafficking of lymphocytes. Obesity increases blood S1P levels in humans and mice. With the world wide increase in obesity linked to consumption of high-fat, high-sugar diets, S1P is emerging as an accomplice in liver pathobiology, including acute liver failure, metabolic syndrome, control of blood lipid and glucose homeostasis, nonalcoholic fatty liver disease, and liver fibrosis. Here, we review recent research on the importance of sphingosine kinases, S1P, and S1PRs in liver pathobiology, with a focus on exciting insights for new therapeutic modalities that target S1P signaling axes for a variety of liver diseases.
Recommended Citation
Rohrbach, T., Maceyka, M., & Spiegel, S. (2017). Sphingosine kinase and sphingosine-1-phosphate in liver pathobiology. Critical reviews in biochemistry and molecular biology, 52(5), 543–553. https://doi.org/10.1080/10409238.2017.1337706
DOI
https://doi.org/10.1080/10409238.2017.1337706